Zimmermann Martine

SEC Form 4 insider trading activity

Zimmermann Martine has filed 3 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Sep 14, 2026.

On the most recent filing, Zimmermann Martine is listed as Director at LIGAND PHARMACEUTICALS INC. Inside the rolling window, Zimmermann Martine reported no open-market purchases and 1 open-market sale totaling $342K in LGND.

Companies traded

Other insiders at LGND

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$342K

reported sales (SEC code S)

Companies

1

in the rolling window

Source
LGND
Zimmermann Martine
Sale$342KSep 14SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Zimmermann Martine made?

Zimmermann Martine has filed 3 SEC Form 4 filings (4 transaction rows) across 1 company since 2025.

Which companies does Zimmermann Martine trade?

Zimmermann Martine has filed SEC Form 4 disclosures for 1 company, including LGND.

When was Zimmermann Martine's most recent SEC Form 4 filing?

Zimmermann Martine's most recent SEC Form 4 filing on Tracefour is dated Sep 14, 2026.

What is Zimmermann Martine's total buy and sell value in the current window?

Inside the rolling retention window, Zimmermann Martine bought $0 and sold $342K based on SEC Form 4 filings.

What was Zimmermann Martine's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 1,200 LGND shares on 2026-09-10, worth $342K, per SEC Form 4 filings.